Google
BCAX 株価分析 — Bicara Therapeutics Inc. Common Stock (Healthcare >> Biotechnology)
BCAX に関するよくある質問
BCAXのROE（自己資本利益率）は？
Bicara Therapeutics Inc. Common StockのROEは-30.61%です。
BCAXの配当利回りは？
Bicara Therapeutics Inc. Common Stockの配当利回りは0.00%です。
BCAXの品質スコア（Quality Score）は？
当社のAIはBCAXの総合財務品質を100点中31点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
BCAXは今が買い時ですか？
当社AIのタイミングスコアは100点中69点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
BCAXはどのセクターに属しますか？
Bicara Therapeutics Inc. Common StockはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
BCAX AI Analysis Summary
Our AI summary for BCAX: Bicara Therapeutics Inc. Common Stock (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -30.61%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 69/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 25.74
Price
-1.36
(-5.02%)
Day Change
|
|
|---|
BCAX, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
44% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 25.74 |
| PBV / Sector |
3.46 / 44,219.29
|
| Earning Per Share | -2.27 |
| PE / Sector |
N/A / 19.28
|
| PEG or PE/Growth / Sector |
N/A / 1.23
|
| Average 1M Daily Value |
14.98 M
GREAT
|
| Average 1W Daily Value |
15.09 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
8% |
| 登録情報 |
| Analyze Date | 2026-08-04 08:01:12 |
| Symbol | BCAX |
| Name | BICARA THERAPEUTICS INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 65.70 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,780.57 / 9,645.64 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 116 Huntington Avenue, Boston, MA, United States, 02116
Phone: 617 468 4219
Website: https://www.bicara.com
Employees: 103
Sector: Healthcare >> Biotechnology
Description: Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
